Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of “Buy” by Analysts

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been assigned a consensus rating of “Buy” from the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $62.7143.

A number of research firms have commented on KNSA. Wells Fargo & Company upped their price target on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Wedbush raised their price objective on Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, June 29th. Zacks Research raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, June 17th. Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Finally, Citigroup increased their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA traded down $1.94 during mid-day trading on Friday, reaching $63.44. 443,134 shares of the company’s stock were exchanged, compared to its average volume of 1,012,453. Kiniksa Pharmaceuticals International has a twelve month low of $26.27 and a twelve month high of $67.53. The firm has a market capitalization of $4.88 billion, a price-to-earnings ratio of 70.49 and a beta of 0.07. The business’s fifty day moving average price is $55.92 and its 200-day moving average price is $48.53.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. The business had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.Kiniksa Pharmaceuticals International’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.11 earnings per share. Analysts predict that Kiniksa Pharmaceuticals International will post 1.25 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, insider John F. Paolini sold 58,424 shares of Kiniksa Pharmaceuticals International stock in a transaction on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the completion of the transaction, the insider owned 65,623 shares of the company’s stock, valued at $3,524,611.33. This trade represents a 47.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 48,565 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the completion of the transaction, the chief executive officer owned 48,565 shares in the company, valued at approximately $2,623,481.30. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 628,427 shares of company stock worth $32,833,228 over the last three months. 51.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in KNSA. EverSource Wealth Advisors LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. bought a new stake in Kiniksa Pharmaceuticals International in the second quarter worth approximately $31,000. KBC Group NV bought a new stake in Kiniksa Pharmaceuticals International in the first quarter worth approximately $34,000. Smartleaf Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $41,000. 53.95% of the stock is owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.